A kind of anti-pancreatic cancer pharmaceutical composition and its application, kit and package

A technology for pancreatic cancer and composition, which is applied in the directions of drug combination, antitumor drug, pharmaceutical formulation, etc., can solve the problems such as the combination of amiloride hydrochloride and erlotinib against pancreatic cancer that has not been seen yet.

Active Publication Date: 2018-10-26
FUDAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have found that amiloride has inhibitory effects on other targets, including Na, which regulates the pH value of tumor cells. + -H + Exchange body 1 (Na + -H + exchanger1, NHE1), and the urokinase-type plasminogen activator (uPA) that mediates tumor migration, invasion and metastasis, so it has a certain anti-tumor effect; but the role of its anti-tumor effect in vitro The effective concentration is in the range of several millimoles, which is a concentration that is difficult to achieve in vivo; therefore, whether amiloride has anti-tumor application prospects in vivo and the in-depth mechanism elucidation still needs further study
[0005] So far, there is no report on the combination of amiloride hydrochloride and erlotinib for the treatment of pancreatic cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of anti-pancreatic cancer pharmaceutical composition and its application, kit and package
  • A kind of anti-pancreatic cancer pharmaceutical composition and its application, kit and package
  • A kind of anti-pancreatic cancer pharmaceutical composition and its application, kit and package

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Cytotoxic effect of amiloride hydrochloride sensitization Erlotinib hydrochloride (Erlotinib) on human pancreatic cancer Bxpc-3 cells

[0032] Experimental Materials:

[0033] Human pancreatic cancer Bxpc-3 cells (Shanghai Cell Bank, Chinese Academy of Sciences) were stored at 37°C, 5% CO 2 Under normal conditions, the medium was RPMI-1640 (Gibco) containing 10% fetal bovine serum (Hyclone). The standard product of amiloride hydrochloride was purchased from China National Institute for the Control of Pharmaceutical and Biological Products, and the mother solution 50mM was prepared by DMSO. Erlotinib hydrochloride raw material is provided by Xuanhong Pharmaceutical (Jinan), and the mother solution is prepared with 10mM DMSO. MTT was purchased from Sigma (USA).

[0034] experimental method:

[0035] 1. Digest the well-differentiated cells with trypsin, suspend them in conventional medium, and adjust the cell density to 5×10 4 cells / ml. 100 μl / well was inocul...

Embodiment 2

[0041] Example 2 Cytotoxic effect of amiloride hydrochloride sensitization erlotinib hydrochloride on human pancreatic cancer PANC-1, Aspc-1 and CFPAC-1 cells

[0042] Experimental Materials:

[0043] Human pancreatic cancer PANC-1, Aspc-1 and CFPAC-1 cells (Shanghai Cell Bank, Chinese Academy of Sciences) were stored at 37°C, 5% CO 2 Under normal conditions, the medium was DMEM, RPMI-1640 and IMDM (Gibco) containing 10% fetal bovine serum (Hyclone). The standard product of amiloride hydrochloride was purchased from China National Institute for the Control of Pharmaceutical and Biological Products, and the mother solution 50mM was prepared by DMSO. Erlotinib hydrochloride raw material is provided by Xuanhong Pharmaceutical (Jinan), and the mother solution is prepared with 10mM DMSO. MTT was purchased from Sigma (USA).

[0044] experimental method:

[0045] 1. Digest the well-differentiated cells with trypsin, suspend them in conventional medium, and adjust the cell density...

Embodiment 3

[0051] Example 3 Long-term growth inhibitory effect of amiloride hydrochloride combined with erlotinib hydrochloride on human pancreatic cancer Bxpc-3, PANC-1, Aspc-1 and CFPAC-1 cells

[0052] Experimental Materials:

[0053] Human pancreatic cancer Bxpc-3, PANC-1, Aspc-1 and CFPAC-1 cells (Shanghai Cell Bank, Chinese Academy of Sciences) were stored at 37°C, 5% CO 2 Under normal conditions, the medium was RPMI-1640, DMEM, RPMI-1640 and IMDM (Gibco) containing 10% fetal bovine serum (Hyclone). The standard product of amiloride hydrochloride was purchased from China National Institute for the Control of Pharmaceutical and Biological Products, and the mother solution 50mM was prepared by DMSO. Erlotinib hydrochloride raw material is provided by Xuanhong Pharmaceutical (Jinan), and the mother solution is prepared with 10mM DMSO. Giemsa stain was purchased from sigma.

[0054] experimental method:

[0055] 1. The well-differentiated cells were trypsinized, suspended in conven...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of biology medicine, and relates to an anti-pancreas cancer pharmaceutical composition, an application, a pill case and a package. The pharmaceutical composition, the pill case and the package contain amiloride with therapeutically effective amount and an epidermal growth factor tyrosine kinase inhibitor EGFR-TKI with therapeutically effective amount which are can be taken as a combined preparation and used in a simultaneous, separating or orderly mode, wherein the mol ratio of amiloride to erlotinib is 500: 1-1: 50. When the pharmaceutical composition, the pill case and the package are used for treating tumor, the drug efficiency which is better than that of erlotinib with individual usage can be obtained, and the clinic chemotherapy effect is increased.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a pharmaceutical composition for anti-pancreatic cancer and its application, a medicine box and a package. Background technique [0002] According to statistical reports, the incidence of pancreatic cancer is increasing year by year, ranking fourth among common malignant tumors in Europe and America, and ninth among malignant tumor deaths in my country. Early diagnosis of pancreatic cancer is difficult. 80% of patients are in the middle and advanced stages when diagnosed, only 10%-15% can undergo radical surgery, and the 5-year survival rate after surgery is only 15%-20%. Typically, the survival of patients with advanced pancreatic cancer is less than 3 months, and the 5-year survival rate is less than 1%. [0003] At present, drug therapy (including chemotherapy, molecular targeted therapy, traditional Chinese medicine and supportive symptomatic treatment) is an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/517A61P35/00A61K31/4965
Inventor 郑媛婷蔡卫民李涛邵腾飞
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap